Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.
During the 2022 Society for Urologic Oncology (SUO) Annual Meeting, CancerNetwork® spoke with Raquibul Hannan, MD, PhD, a professor in the Department of Radiation Oncology, Urology and Immunology at the University of Texas Southwestern Medical Center in Dallas, about the next steps for researching stereotactic radiation in the management of metastatic kidney cancer.
According to Hannan, future clinical trials in this setting will include the use of procedures like cytoreduction and checkpoint inhibitor immunotherapy to further explore the potential of stereotactic radiation.
“…These are going to be very informative and interesting trials to look forward to,” he said.
There are some interesting ongoing clinical trials that are looking into both the cytoreductive property of stereotactic radiation [and] also the immunogenic potential. The immunogenic potential is something that we have seen in our phase 2 oligoprogressive study, where we saw that patients that are on checkpoint inhibitors getting oligoprogressive [disease] side-treated with stereotactic radiation were doing much better than those that are on [tyrosine kinase inhibitors]. And this is being investigated [in] 2 trials: one of them is called the CYTOSHRINK trial [NCT04090710] by a Canadian group, and the SAMURAI trial [NCT05327686] by NRG, headed by Rana McKay. Both of them are looking to do cytoreduction as well as immune stimulation in the setting of checkpoint inhibitor immunotherapy for patients [with metastatic renal cell carcinoma) who have primary intact, and these are going to be very informative and interesting trials to look forward to.